'Her2 negative' presentation slideshows

DISSECTING THE DECISION Optimizing the Use of CDK4/6 Inhibitors in the Management of

DISSECTING THE DECISION Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive, HER2-Negative Metastatic Breast Cancer. Co-Chairs. Neil Love, MD Sara M Tolaney, MD, MPH. Faculty. Neelima Denduluri , MD Shom Goel , BMedSci, MBBS, PhD Erika Hamilton, MD Komal Jhaveri , MD

1.95k views • 194 slides

1.26k views • 112 slides

AVADO

A randomized, double-blind study of bevacizumab in combination with docetaxel as first-line treatment of patients with HER2-negative locally recurrent or metastatic breast cancer: efficacy and safety. AVADO. David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom.

609 views • 26 slides

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer

63 views • 1 slides